Italy's payback bill and its innovation label belong in the same forecast

Two AIFA notices, one commercial reality

On 29 October AIFA fixed each marketing authorisation holder's 2025 payback share for direct-purchase spending in determination 1531/2026. The burden is assigned company by company and by region. AIFA made no changes after consulting companies, and payment falls due 30 days after the determination takes effect. A day later, AIFA's innovative medicines update for September 2026 recorded no new innovativeness recognitions. It confirmed that belantamab mafodotin (Blenrep) and inavolisib (Itovebi) were refused the status for their assessed indications.

Read separately, these look like routine administration. Read together, they say something blunt about Italy. The price you launch at is not the price you keep. Spending in one year produces a liability that is settled in the next, on a short fuse. The innovation label is one of the few formal levers a company can pull to shape its position in that system. My view is that too many Italian forecasts treat the label as an upside and the payback as an accounting accrual. They should be one integrated model, owned by one team.

Why the label deserves dossier-grade effort

Innovative status in Italy is generally associated with preferential treatment, such as dedicated funding and quicker regional access. The detail varies by product, so check the current rules. If it matters that much, an application for it is a core access deliverable, not a courtesy filing after the reimbursement discussion.

The September update shows the downside. Two oncology products were assessed and refused. The records do not say why, and I will not guess. The point stands that a refusal is a live outcome, even for products in a therapeutic area where innovation claims are common. A plan that assumes the label will be granted is a plan with a hole in it.

The payback notice shows the other half. Because the 2025 shares are final, with no changes after consultation, whatever leverage a company had lay earlier. It lay in how the product was priced and positioned, and in whether it carried a status that might have changed its commercial trajectory. By the time the determination arrives, the only decision left is how to pay.

The strongest counter-argument

The best objection is that this is overreach. Payback is set by system-wide overspend and allocated by formula. No single company controls it, and the innovation decision belongs to AIFA's assessment, not to the applicant's planning. Spending effort on modelling what you cannot influence looks like false precision. Two refusals and zero new recognitions in one month is also a thin basis for any claim about trends, and I do not make one.

I accept most of that. But the argument for integrated modelling does not depend on controlling the outcome. It depends on knowing your exposure. A 30-day payment window is an acute cash-planning problem for any company that has not provisioned for it. And a company that has not stress-tested a no-label scenario will discover its true Italian margin only when the decision lands. Uncertainty is a reason to model more carefully, not to model less.

What I would do

Put Italy's retrospective liability and its innovation outcome on the same page of the launch case. Run the base case without the label, and treat the label as the upside scenario. Give finance and market access shared sight of regional direct-purchase exposure, so that a determination like 1531/2026 is a confirmation of numbers already in the plan, not a surprise. Then audit the innovativeness evidence package as early as you would audit a pricing submission.

— The Editor, VigiEye